Dupixent, which is expected to benefit infants and young children with eczema, has been granted priority review

On February 10, 2022, Regeneron and Sanofi announced that the U.

Atopic dermatitis is a chronic type 2 inflammatory skin disease that occurs in 85 to 90% of patients before age 5 and often persists into adulthood

Dupilumab is a fully humanized monoclonal antibody that selectively inhibits the key interleukin 4 (IL-4) and interleukin 13 (IL-13) signaling pathways and reduces the pathological response of type 2 inflammation , Mechanistically treat type 2 inflammation-related diseases, such as asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP) and atopic dermatitis

This sBLA submission is supported by positive data from a pivotal Phase 3 clinical trial

Specifically, 28% of subjects in the dupilumab group achieved clear or almost clear skin compared to the placebo group (4%, p≤0.

References:

[1] FDA Accepts Dupixent® (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis.